Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-18T18:17:14.035Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug therapy in treatment-resistant depression

Published online by Cambridge University Press:  31 January 2018

G. S. Malhi  and
A. E. Farmer
G. S. Malhi
Affiliation:
National Unit for Affective Disorders, Maudsley Hospital, Denmark Hill, London SE5 8AZ
A. E. Farmer
Affiliation:
National Unit for Affective Disorders, Maudsley Hospital, Denmark Hill, London SE5 8AZ
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 175 , Issue 4 , October 1999 , pp. 390 - 391
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

References

Danjou, P. & Hackett, D. (1995) Safety and tolerance profile of venlafaxine. International Journal of Psychopharmacology, 10 (suppl. 2), 15–20.Google Scholar
Hodgkiss, A. D., McCarthy, P. T., Suite, A. N., et al (1995) High dose tertiary amine tricyclic antidepressants in the treatment of severe refractory depression. The central role of plasma concentration estimations. Human Psychopharmacology, 10, 407–415.Google Scholar
Poirier, M.-F. & Boyer, P. (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry, 175, 12–16.Google Scholar
Weiss, J. M., Demetrikopoulo, K. & West, C. H. K. (1995/1996) Hypothesis linking the noradrenergic and dopaminergic systems in depression. Depression, 3, 225–245.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.